MAGNITUDE: A Phase 3, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of NTLA-2001 in Participants with ATTR-CM

Grants and Contracts Details

StatusActive
Effective start/end date1/18/241/18/26

Funding

  • Intellia Therapeutics Incorporated: $12,500.00